Genmab A/S (GNMSF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:42PM EDT
| Previous close | 325.29 |
| Open | 315.16 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 315.16 - 340.08 |
| 52-week range | 260.25 - 500.92 |
| Volume | |
| Avg. volume | 1,924 |
| Market cap | 21.526B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 61.59 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Should You Buy Genmab (GMAB) Ahead of Earnings?
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Zacks
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.
- Zacks
Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.
© 2022 Yahoo. All rights reserved.
